BOOK
Angioedema, An Issue of Immunology and Allergy Clinics of North America, E-Book
(2017)
Additional Information
Book Details
Abstract
This issue of Immunology and Allergy Clinics, guest edited by Mariana Castells, is devoted to Drug Hypersensitivity and Desensitizations. Articles in this issue include: Principles and Practice of Drug Desensitization; Incidence and Prevalence of Drug Hypersensitivity; Drug-Induced Anaphylaxis; Penicillin and Beta Lactam Hypersensitivity; Platins Chemotherapy Hypersensitivity: Prevalence and Management; Monoclonal Antibodies Hypersensitivity: Prevalence and Management; Injectable Drugs and MoAbs Reactions and Management with Desensitization; Delayed Cutaneous Reactions to Antibiotics, Management with Desensitization; Management of Children with Hypersensitivity to Antibiotics and MoAbs; Taxenes Hypersensitivity and Management; Progesterone Autoimmune Dermatitis; Severe Delayed Drug Reaction: Role of Genetics and Viral Infections; andAspirin and NSAIDS Hypersensitivity and Management.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Angioedema | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Foreword: Angioedema: An Orphan Symptom with Its Own Orphan Disease | vii | ||
| Preface: Angioedema: Challenges and Insights | vii | ||
| The Clinical Evaluation of Angioedema | vii | ||
| Histaminergic Angioedema | vii | ||
| Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema | vii | ||
| Acquired C1 Inhibitor Deficiency | viii | ||
| Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade | viii | ||
| Laboratory Approaches for Assessing Contact System Activation | viii | ||
| Acute Management of Hereditary Angioedema Attacks | viii | ||
| Prophylactic Therapy for Hereditary Angioedema | ix | ||
| Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment | ix | ||
| Emerging Therapies in Hereditary Angioedema | ix | ||
| Burden of Illness and Quality-of-Life Measures in Angioedema Conditions | ix | ||
| Pharmacoeconomics of Orphan Disease Treatment with a Focus on Hereditary Angioedema | x | ||
| IMMUNOLOGYAND ALLERGY\rCLINICS OF NORTH AMERICA\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| November 2017 | xi | ||
| February 2018 | xi | ||
| May 2018 | xi | ||
| RECENT ISSUES | xi | ||
| May 2017 | xi | ||
| February 2017 | xi | ||
| November 2016 | xi | ||
| Foreword: Angioedema: An Orphan Symptom with Its Own Orphan Disease\r | xiii | ||
| Preface:\rAngioedema: Challenges and Insights | xv | ||
| The Clinical Evaluation of Angioedema | 449 | ||
| Key points | 449 | ||
| INTRODUCTION | 449 | ||
| SIGNS AND SYMPTOMS OF ANGIOEDEMA | 450 | ||
| PATHOPHYSIOLOGY OF ANGIOEDEMA | 450 | ||
| Histamine-Mediated Pathways | 450 | ||
| Bradykinin-Mediated Pathways | 452 | ||
| Angioedema Resulting Through Cyclooxygenase 1 Inhibition | 454 | ||
| Type III Hypersensitivity Reactions | 454 | ||
| CLASSIFICATION OF ANGIOEDEMA | 454 | ||
| APPROACH TO THE CLINICAL EVALUATION AND DIAGNOSTIC WORKUP | 454 | ||
| Histamine-Mediated Angioedema | 454 | ||
| Clinical features | 454 | ||
| Allergic angioedema | 454 | ||
| Pseudoallergic angioedema | 455 | ||
| Idiopathic angioedema | 455 | ||
| DIAGNOSTIC EVALUATION OF HISTAMINE-MEDIATED ANGIOEDEMA | 456 | ||
| Bradykinin-Mediated Angioedema | 457 | ||
| Clinical features | 457 | ||
| Hereditary angioedema | 457 | ||
| Acquired agioedema | 458 | ||
| Angiotensin-converting enzyme–inhibitor induced angioedema | 459 | ||
| DIAGNOSTIC EVALUATION OF BRADYKININ-MEDIATED ANGIOEDEMA | 459 | ||
| Essential Components of the Clinical History | 460 | ||
| An Algorithmic Approach to Diagnosis of Angioedema | 460 | ||
| FUTURE CONSIDERATIONS | 460 | ||
| REFERENCES | 464 | ||
| Histaminergic Angioedema | 467 | ||
| Key points | 467 | ||
| INTRODUCTION | 467 | ||
| ACUTE ANGIOEDEMA | 469 | ||
| Allergic (Immunoglobulin E–Mediated) Angioedema | 469 | ||
| Presentation | 469 | ||
| Pathophysiology | 469 | ||
| Nonallergic Mast-Cell–Mediated Acute Angioedema | 470 | ||
| Presentation | 470 | ||
| Pathophysiology | 470 | ||
| CHRONIC ANGIOEDEMA | 470 | ||
| Histamine-Mediated Angioedema with Chronic Urticaria | 470 | ||
| Physical Urticaria | 471 | ||
| Presentation | 471 | ||
| Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema | 483 | ||
| Key points | 483 | ||
| INTRODUCTION | 483 | ||
| ANGIOEDEMA ASSOCIATED WITH NONSTEROIDAL ANTIINFLAMMATORY DRUG USE | 484 | ||
| ANGIOTENSIN-CONVERTING ENZYME INHIBITOR–ASSOCIATED ANGIOEDEMA | 485 | ||
| Clinical Features of Angiotensin-converting Enzyme Inhibitor–associated Angioedema | 485 | ||
| Epidemiology of and Risk Factors for Angiotensin-converting Enzyme Inhibitor–associated Angioedema | 485 | ||
| Pathophysiology of Angiotensin-converting Enzyme Inhibitor–associated Angioedema | 486 | ||
| Genetics of Angiotensin-converting Enzyme Inhibitor–associated Angioedema | 487 | ||
| Management of Angiotensin-converting Enzyme Inhibitor–associated Angioedema | 488 | ||
| DIPEPTIDYL PEPTIDASE 4 INHIBITORS AND ANGIOEDEMA | 489 | ||
| COMBINED ANGIOTENSIN RECEPTOR BLOCKER/NEPRILYSIN INHIBITOR AND ANGIOEDEMA | 489 | ||
| TISSUE-TYPE PLASMINOGEN ACTIVATOR–INDUCED ANGIOEDEMA | 490 | ||
| SUMMARY | 490 | ||
| REFERENCES | 490 | ||
| Acquired C1 Inhibitor Deficiency | 497 | ||
| Key points | 497 | ||
| INTRODUCTION | 497 | ||
| EPIDEMIOLOGY | 498 | ||
| RISK FACTORS | 499 | ||
| CLINICAL FEATURES | 499 | ||
| PATHOPHYSIOLOGY | 500 | ||
| DIFFERENTIAL DIAGNOSIS | 501 | ||
| MANAGEMENT | 502 | ||
| Symptom Control | 502 | ||
| Acute Treatment | 502 | ||
| Prophylaxis | 503 | ||
| Short-term Prophylaxis | 503 | ||
| Long-term Prophylaxis | 503 | ||
| Treatment of Acquired Angioedema due to C1-INH Deficiency and Underlying Systemic Conditions | 504 | ||
| PROGNOSIS | 504 | ||
| CURRENT CONTROVERSIES | 504 | ||
| Pathophysiology | 504 | ||
| C1 Esterase Inhibitor Replacement Therapy | 504 | ||
| Rituximab Therapy | 507 | ||
| REFERENCES | 507 | ||
| Pathogenesis of Hereditary Angioedema | 513 | ||
| Key points | 513 | ||
| INTRODUCTION | 513 | ||
| THE ROLE OF C1 INHIBITOR IN COMPLEMENT ACTIVATION | 514 | ||
| BRADYKININ IS THE MEDIATOR OF SWELLING IN HEREDITARY ANGIOEDEMA TYPES I AND II | 515 | ||
| THE PATHWAY(S) OF BRADYKININ FORMATION IN TYPES I AND II HEREDITARY ANGIOEDEMA | 517 | ||
| VASOPERMEABILITY OWING TO BRADYKININ | 518 | ||
| ASSEMBLY AND ACTIVATION OF THE BRADYKININ-FORMING CASCADE ON ENDOTHELIAL CELLS | 518 | ||
| HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR: NEW FORMS OF HEREDITARY ANGIOEDEMA | 521 | ||
| REFERENCES | 522 | ||
| Laboratory Approaches for Assessing Contact System Activation | 527 | ||
| Key points | 527 | ||
| INTRODUCTION | 527 | ||
| BRADYKININ-MEDIATED ANGIOEDEMA | 528 | ||
| Role of Bradykinin in Hereditary Angioedema due to C1 Inhibitor Deficiency | 528 | ||
| Role of Bradykinin in Hereditary Angioedema with Normal C1 Inhibitor | 529 | ||
| Role of Bradykinin in Other Forms of Angioedema | 529 | ||
| LABORATORY DIAGNOSIS OF ANGIOEDEMA | 530 | ||
| Angioedema Associated with C1 Inhibitor Deficiency | 530 | ||
| Bradykinin-Mediated Angioedema with Normal C1 Inhibitor | 531 | ||
| BIOMARKERS OF CONTACT SYSTEM ACTIVATION | 531 | ||
| Measurement of C1 Inhibitor Levels | 531 | ||
| C4 Levels | 532 | ||
| Measurement of Protease-Inhibitor Complexes | 532 | ||
| Cleavage of Zymogen Proteases | 533 | ||
| High-Molecular-Weight Kininogen Cleavage | 533 | ||
| Bradykinin Levels | 533 | ||
| Measurement of Kallikrein Activity | 533 | ||
| Other Assays | 533 | ||
| SUMMARY | 533 | ||
| REFERENCES | 535 | ||
| Acute Management of Hereditary Angioedema Attacks | 541 | ||
| Key points | 541 | ||
| INTRODUCTION | 541 | ||
| MEDICATIONS FOR TREATING ACUTE ATTACKS | 542 | ||
| PLASMA-DERIVED C1 INHIBITOR THERAPY | 542 | ||
| Berinert | 542 | ||
| Studies of efficacy | 542 | ||
| Cinryze | 542 | ||
| Onset of Action of Plasma-Derived C1 Inhibitors | 543 | ||
| Rebound and Relapse | 543 | ||
| SPECIFIC CIRCUMSTANCES | 543 | ||
| Laryngeal Attacks | 543 | ||
| Treatment in Pediatric Patients | 543 | ||
| Pregnancy and Breast Feeding | 544 | ||
| ADVERSE EVENTS WITH C1 INHIBITOR PRODUCTS | 544 | ||
| Viral Transmission | 544 | ||
| Thromboembolic Events | 544 | ||
| Immunogenicity | 545 | ||
| INDICATION AND ADMINISTRATION | 545 | ||
| RECOMBINANT C1 INHIBITOR CONESTAT ALFA | 545 | ||
| Introduction | 545 | ||
| Trial Data | 547 | ||
| Onset of Action | 547 | ||
| Rebound and Relapse | 547 | ||
| Response by Anatomic Location | 547 | ||
| SPECIAL POPULATIONS | 548 | ||
| Pediatric Use | 548 | ||
| Pregnancy and Breast Feeding | 548 | ||
| Adverse Events | 548 | ||
| Immunogenicity | 548 | ||
| Thrombogenicity | 548 | ||
| Administration | 548 | ||
| ECALLANTIDE | 548 | ||
| Introduction | 548 | ||
| Clinical Trial Data | 549 | ||
| Onset of Action | 549 | ||
| Rebound | 549 | ||
| Laryngeal Attacks | 549 | ||
| Special Populations | 549 | ||
| Adverse Events | 550 | ||
| Anaphylaxis | 550 | ||
| Immunogenicity | 550 | ||
| Administration | 550 | ||
| ICATIBANT | 550 | ||
| Introduction | 550 | ||
| Studies of Efficacy | 550 | ||
| Laryngeal Attacks | 551 | ||
| Adverse Events | 551 | ||
| Indications and Administration | 551 | ||
| Self-Administration | 551 | ||
| Other Considerations | 552 | ||
| Lack of efficacy of tranexamic acid for acute hereditary angioedema attacks | 552 | ||
| FRESH FROZEN PLASMA | 552 | ||
| Preparedness to Intubate | 552 | ||
| Patient Self-Administration | 552 | ||
| SUMMARY | 552 | ||
| REFERENCES | 553 | ||
| Prophylactic Therapy for Hereditary Angioedema | 557 | ||
| Key points | 557 | ||
| INTRODUCTION | 557 | ||
| WHEN PROPHYLAXIS IS INDICATED | 558 | ||
| ATTENUATED ANDROGENS | 558 | ||
| Efficacy | 558 | ||
| Side Effects of Attenuated Androgens | 559 | ||
| Abnormalities in Hepatic Enzymes | 559 | ||
| Liver Neoplasms | 560 | ||
| Cardiovascular Risks and Lipid Profiles | 560 | ||
| Hemorrhagic Cystitis | 561 | ||
| Current Guidelines for the Use of Androgen Therapy as Prophylaxis | 561 | ||
| C1-INHIBITOR | 561 | ||
| Efficacy | 561 | ||
| Dosing and Delivery Route | 562 | ||
| Ongoing Developments | 562 | ||
| Side Effects | 562 | ||
| Thromboembolic Events | 563 | ||
| Theoretic Viral/Prion Risk | 563 | ||
| TRANEXAMIC ACID | 563 | ||
| Safety Profile and Side Effects | 563 | ||
| PROGESTAGENS | 564 | ||
| Side Effect Profile | 564 | ||
| Use as Prophylaxis | 564 | ||
| SHORT-TERM PROPHYLAXIS | 564 | ||
| Introduction | 564 | ||
| Options for Short-term Prophylaxis | 565 | ||
| C1 Inhibitor | 565 | ||
| Attenuated Androgens | 565 | ||
| Tranexamic Acid | 565 | ||
| SUMMARY | 566 | ||
| REFERENCES | 566 | ||
| Hereditary Angioedema with Normal C1 Inhibitor | 571 | ||
| Key points | 571 | ||
| INTRODUCTION | 571 | ||
| THE PATHOPHYSIOLOGY OF HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR | 572 | ||
| THE GENETICS OF HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR | 573 | ||
| CLINICAL FEATURES OF HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR | 575 | ||
| DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR | 576 | ||
| Diagnosis | 576 | ||
| Differential Diagnosis | 576 | ||
| TREATMENT OF HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR | 577 | ||
| On-demand Treatment | 577 | ||
| Short-term Prophylaxis | 578 | ||
| Long-term Prophylaxis | 578 | ||
| REFERENCES | 579 | ||
| Emerging Therapies in Hereditary Angioedema | 585 | ||
| Key points | 585 | ||
| INTRODUCTION | 585 | ||
| HISTAMINERGIC VERSUS BRADYKININ PATHWAYS | 586 | ||
| Treatment of Histamine Versus Bradykinin-Mediated Angioedema | 587 | ||
| RECENT DEVELOPMENTS IN HEREDITARY ANGIOEDEMA THERAPY | 587 | ||
| Hereditary Angioedema Therapy for Pediatrics | 587 | ||
| Clinical trials | 587 | ||
| EMERGING THERAPIES FOR LONG-TERM PROPHYLAXIS | 588 | ||
| Treatments in Human Studies | 588 | ||
| Complement component 1 esterase inhibitor concentrates | 588 | ||
| Subcutaneous complement component 1 esterase inhibitor | 588 | ||
| Recombinant human C1INH | 590 | ||
| Monoclonal antibody inhibitor of kallikrein | 591 | ||
| Lanadelumab (DX2930 or SHP643) | 591 | ||
| Oral kallikrein inhibitors | 591 | ||
| Avoralstat (BCX4161) | 591 | ||
| BCX7353 | 591 | ||
| KVD818 | 592 | ||
| Antisense targeting prekallikrein | 592 | ||
| Ionis PKKRx | 592 | ||
| Treatments in Preclinical Studies | 592 | ||
| Factor XII | 592 | ||
| ALN-F12 | 592 | ||
| ARC-F12 | 592 | ||
| Monoclonal antibody antifactor XIIa | 593 | ||
| Gene therapy | 593 | ||
| ACUTE THERAPY: CONCEPTUAL | 593 | ||
| Oral Kallikrein Inhibitor | 593 | ||
| FUTURE CONSIDERATIONS AND SUMMARY | 593 | ||
| REFERENCES | 594 | ||
| Burden of Illness and Quality-of-Life Measures in Angioedema Conditions | 597 | ||
| Key points | 597 | ||
| INTRODUCTION | 598 | ||
| HEALTH-RELATED QUALITY-OF-LIFE QUESTIONNAIRES | 598 | ||
| Generic Questionnaires | 598 | ||
| Short Form 36 Health Survey | 598 | ||
| EuroQoL | 598 | ||
| Dermatology-Specific Questionnaires | 599 | ||
| Dermatology Life Quality Index | 599 | ||
| Skindex-29 | 599 | ||
| Angioedema-Specific Questionnaires | 599 | ||
| AE-QoL | 599 | ||
| HAE-QoL | 599 | ||
| Other Health-Related Quality-of-Life Measures | 600 | ||
| Quality-adjusted life-year | 600 | ||
| HEALTH-RELATED QUALITY OF LIFE AND BURDEN OF DISEASE IN HISTAMINERGIC ANGIOEDEMA | 600 | ||
| HEALTH-RELATED QUALITY OF LIFE AND BURDEN OF DISEASE IN HEREDITARY ANGIOEDEMA CAUSED BY C1-INHIBITOR DEFICIENCY | 601 | ||
| HEALTH-RELATED QUALITY OF LIFE AND BURDEN OF DISEASE IN OTHER BRADYKININ-INDUCED ANGIOEDEMAS | 611 | ||
| FUTURE CONSIDERATIONS/SUMMARY | 611 | ||
| REFERENCES | 612 | ||
| Pharmacoeconomics of Orphan Disease Treatment with a Focus on Hereditary Angioedema | 617 | ||
| Key points | 617 | ||
| OVERVIEW | 617 | ||
| ORPHAN DRUG DEVELOPMENT POLICIES AND REIMBURSEMENT ISSUES | 618 | ||
| PREVALENCE OF ORPHAN DISEASES | 618 | ||
| IMPACT OF NEW THERAPIES FOR HEREDITARY ANGIOEDEMA | 619 | ||
| COST OF HEREDITARY ANGIOEDEMA CARE BEFORE 2008 IN THE UNITED STATES | 622 | ||
| BURDEN OF DISEASE | 622 | ||
| INNOVATIVE TREATMENT PARADIGMS | 623 | ||
| SUMMARY | 624 | ||
| REFERENCES | 625 |